Patents by Inventor Dominique Heymann

Dominique Heymann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-metastatic marine bacterial exopolysaccharide derivative and uses thereof
    Patent number: 11219638
    Abstract: The invention provides a low-molecular-weight (15 kDa) over-sulfated exopolysaccharide (GYS15) prepared from a marine native exopolysaccharide excreted by a mesophilic marine bacterium from a deep-sea hydrothermal environment, and relates to the use of this low-molecular-weight over-sulfated exopolysaccharide for the prevention or inhibition of metastases formation.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: January 11, 2022
    Assignees: INSTITUT FRANCAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER (IFREMER), UNIVERSITE DE NANTES, INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Sylvia Colliec-Jouault, Corinne Sinquin, Jacqueline Ratiskol, Dominique Heymann, Carmen Ruiz-Velasco, Julie Chesneau
  • Anti IL-34 antibodies
    Patent number: 10703813
    Abstract: The present disclosure relates to novel anti IL-34 antibodies or antigen-binding fragments thereof specifically binding cytokine IL-34 with high affinity, the method of obtaining of these antibodies and their therapeutic use.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: July 7, 2020
    Assignees: UNIVERSITE DE NANTES, CHU NANTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Dominique Heymann, Aude Segaliny, Régis Brion
  • AN ANTI-METASTATIC MARINE BACTERIAL EXOPOLYSACCHARIDE DERIVATIVE AND USES THEREOF
    Publication number: 20180280427
    Abstract: The invention provides a low-molecular-weight (15 kDa) over-sulfated exopolysaccharide (GYS15) prepared from a marine native exopolysaccharide excreted by a mesophilic marine bacterium from a deep-sea hydrothermal environment, and relates to the use of this low-molecular-weight over-sulfated exopolysaccharide for the prevention or inhibition of metastases formation.
    Type: Application
    Filed: September 28, 2016
    Publication date: October 4, 2018
    Inventors: Sylvia Colliec-Jouault, Corinne Sinquin, Jacqueline Ratiskol, Dominique Heymann, Carmen Ruiz-Velasco, Julie Chesneau
  • ANTI IL-34 ANTIBODIES
    Publication number: 20170342148
    Abstract: The present disclosure relates to novel anti IL-34 antibodies or antigen-binding fragments thereof specifically binding cytokine IL-34 with high affinity, the method of obtaining of these antibodies and their therapeutic use.
    Type: Application
    Filed: December 21, 2015
    Publication date: November 30, 2017
    Applicants: Universite de Nantes, Chu Nantes, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Dominique Heymann, Aude Segaliny, Régis Brion
  • Peptides targeting receptor activator of nuclear factor-?B (RANK) and their applications
    Patent number: 9403873
    Abstract: The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: August 2, 2016
    Assignees: UNIVERSITE DE NANTES
    Inventors: Dominique Heymann, Stéphane Teletchea, Verena Stresing
  • PEPTIDES TARGETING RECEPTOR ACTIVATOR OF NUCLEAR FACTOR - KAPPA B (RANK) AND THEIR APPLICATIONS
    Publication number: 20140371150
    Abstract: The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 18, 2014
    Inventors: Dominique Heymann, Stéphane Teletchea, Verena Stresing
  • Hydroxy-bisphosphonic acid derivatives as vector targeting bone tissue
    Patent number: 8361993
    Abstract: The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: -n and m denote, independently of one another, an integer ranging from 1 to 4, —X denotes an oxygen atom or an N—R3 group, —R1 and R3 denote, independently of one another, a linear or branched C1 to C6 alkyl group, and —R2 denotes a residue of a molecule of therapeutic or diagnostic interest, or pharmaceutically acceptable salts of said derivatives, and also the method for the preparation thereof and the therapeutic or diagnostic use thereof.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: January 29, 2013
    Assignees: Universite de Nantes, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Maxim Egorov, Yannick Fortun, Dominique Heymann, Jacques Lebreton, Monique Mathe, Marc Padrines, Francoise Redini
  • HYDROXY-BISPHOSPHONIC ACID DERIVATIVES AS VECTOR TARGETING BONE TISSUE
    Publication number: 20100311695
    Abstract: The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: -n and m denote, independently of one another, an integer ranging from 1 to 4, —X denotes an oxygen atom or an N—R3 group, —R1 and R3 denote, independently of one another, a linear or branched C1 to C6 alkyl group, and —R2 denotes a residue of a molecule of therapeutic or diagnostic interest, or pharmaceutically acceptable salts of said derivatives, and also the method for the preparation thereof and the therapeutic or diagnostic use thereof.
    Type: Application
    Filed: January 5, 2009
    Publication date: December 9, 2010
    Inventors: Maxim Egorov, Yannick Fortun, Dominique Heymann, Jacques Lebreton, Monique Mathe, Marc Padrines, Francoise Redini